Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation


Ayanoglu M., Korgali E., Sezer T., Aydin H. I., Sonmez F. M.

BRAIN & DEVELOPMENT, cilt.42, sa.5, ss.418-420, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42 Sayı: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.braindev.2020.02.001
  • Dergi Adı: BRAIN & DEVELOPMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE, Psycinfo
  • Sayfa Sayıları: ss.418-420
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels.